Request for Information (RFI): Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases (CRID)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIAID

Contract Value

Not provided

Codes & Classification
Solicitation Number

NIH-NIAID-RFI-001-26

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

R702

Additional Details
Set Aside

NONE

Place of Performance

UNITED STATES

SourceSAM
Documents1
The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), has issued a Request for Information (RFI) to gather input from industry stakeholders regarding the future re-competition of its Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases (CRID) contract. This RFI, identified by procurement number NIH-NIAID-RFI-001-26, is intended solely for information and planning purposes and does not constitute a solicitation or a commitment to award a contract. NIAID’s Division of Microbiology and Infectious Diseases (DMID) supports a comprehensive portfolio of extramural clinical research aimed at understanding, treating, and preventing infectious, immunologic, and allergic diseases. The research encompasses a wide array of activities, including single-site and multi-center clinical trials (spanning Phase 0-4 therapeutics and vaccines), studies on new vaccine formulations and delivery methods, surveillance and cohort studies for pathogens of interest, evaluation of novel diagnostics, and trials exploring additional uses for approved therapies. While the majority of clinical sites are domestic, the program also supports international studies as needed. To ensure regulatory compliance and effective oversight of its clinical research activities, NIAID relies on the SDCC to provide centralized data management, statistical analysis, and specimen tracking services. These functions are critical for standardized deliverables, regulatory reporting, safety oversight, and monitoring across the clinical research portfolio. The primary objectives of this RFI are to: 1. Engage with industry early in the acquisition process, prior to the release of a formal Request for Proposals (RFP). 2. Assess current market capabilities and vendor offerings relevant to SDCC services. 3. Solicit input on industry best practices to inform the development of a future Statement of Work (SOW). 4. Promote fair and open competition in accordance with federal acquisition regulations. The anticipated scope of the future SDCC contract will likely include, but is not limited to, centralized data management, statistical support, and specimen tracking for a diverse range of clinical research activities in infectious diseases. Respondents are encouraged to provide feedback on their capabilities, innovative approaches, and recommendations for best practices in these areas. Key details for interested parties include: - NAICS Code: 541714 (Research and Development in Biotechnology, except Nanobiotechnology) - Product Service Code: R702 - Place of Performance: United States - Set-Aside Status: None (open to all qualified vendors) - Contracting Entity: National Institutes of Health, NIAID - Primary Contact: Miranda Adams ([email protected]) - Secondary Contact: Jonathan Bryan ([email protected]) - Notice Status: Active - Notice URL: https://sam.gov/opp/a64eda19fb5c4d60b91efff1456ddb40/view This RFI represents an opportunity for organizations with expertise in data coordination, statistical analysis, and specimen management within the context of clinical research in infectious diseases to inform the government’s acquisition strategy and future requirements. Interested parties should review the full RFI (attached to the notice) and submit their responses by August 7, 2026. All responses will be used for planning purposes only and will not be returned. Contractors evaluating this opportunity should consider their experience in supporting large-scale, multi-site clinical research, their ability to meet rigorous regulatory and reporting requirements, and their capacity to deliver innovative, efficient, and compliant data and specimen management solutions in the field of infectious diseases.